Opdivo and Systemic candida - a phase IV clinical study of FDA data

Summary:

Systemic candida is reported as a side effect among people who take Opdivo (nivolumab), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Yervoy, and have Lung cancer - non-small cell.

The phase IV clinical study analyzes which people have Systemic candida when taking Opdivo. It is created by eHealthMe based on reports of 56,294 people who have side effects when taking Opdivo from the FDA, and is updated regularly.

What is Opdivo?

Opdivo has active ingredients of nivolumab. eHealthMe is studying from 56,331 Opdivo users. Check the latest studies of Opdivo.

What is Systemic candida?

Systemic candida (whole body fungal infection) is found to be associated with 278 drugs and 410 conditions by eHealthMe. Check the latest studies of Systemic candida.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

56,294 people reported to have side effects when taking Opdivo.
Among them, 14 people (0.02%) have Systemic candida.

Among these 14 people:

How long have people been on Opdivo when they have Systemic candida? *

What is the gender of people who have Systemic candida when taking Opdivo? *

female: 35.71 %
male: 64.29 %

What is the age of people who have Systemic candida when taking Opdivo? *

What are other drugs people take besides Opdivo? *

What are other side effects people have besides Systemic candida? *

Myasthenia Gravis (a chronic condition that causes muscles to tire and weaken easily): 6 people, 42.86%
Ventricular Tachycardia (rapid heartbeat that originates in one of the lower chambers (the ventricles) of the heart): 5 people, 35.71%
Cardiac Failure: 5 people, 35.71%
Autoimmune Myocarditis (inflammation of the heart muscle by immune system disorder): 4 people, 28.57%
Diabetic Ketoacidosis (diabetic ketoacidosis (dka) is high concentrations of ketone bodies): 3 people, 21.43%
Alanine Aminotransferase Increased: 3 people, 21.43%
Aspartate Aminotransferase Increased: 3 people, 21.43%
Escherichia Infection (bacterial infection by escherichia coli): 2 people, 14.29%
Enterocolitis (inflammation of the digestive tract, involving enteritis of the small intestine and colitis of the colon): 2 people, 14.29%
Dizziness: 2 people, 14.29%

What are the existing conditions these people have? *

Lung Cancer - Non-Small Cell (lung cancer): 5 people, 35.71%
Sarcoma (rare cancers that develop in the muscle, bone, nerves, cartilage, tendons, blood vessels and the fatty and fibrous tissues): 3 people, 21.43%
Non-Small Cell Lung Cancer Metastatic (type of epithelial lung cancer spreads to other parts): 2 people, 14.29%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 2 people, 14.29%
Oesophageal Carcinoma (cancer tumour of oesophagus): 1 person, 7.14%
Non-Small Cell Lung Cancer Recurrent (type of epithelial lung cancer reoccurrence): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Opdivo and have Systemic candida?

- Check whether Systemic candida is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Opdivo:

Opdivo (56,331 reports)

Browse all side effects of Opdivo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Systemic candida:

Systemic candida (278 drugs)

Browse all the conditions that are associated with Systemic candida:

Systemic candida (410 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on nivolumab (the active ingredients of Opdivo) and Opdivo (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.